COPD Clinical Trials in the UK (2026)

Chronic Obstructive Pulmonary Disease (COPD) affects over 1.2 million people in the UK, making it one of the country's most prevalent long-term conditions. If you're living with COPD — whether it's emphysema, chronic bronchitis, or both — clinical trials may offer access to new treatments before they become widely available.

This guide covers the current landscape of COPD clinical trials in the UK, what researchers are studying, and how to find a trial that's right for you.

What is COPD?

COPD is a progressive lung disease that causes airflow obstruction, making it difficult to breathe. It encompasses two main conditions:

• Emphysema — damage to the air sacs (alveoli) in the lungs, reducing their ability to expand and contract
• Chronic bronchitis — long-term inflammation of the airways, causing persistent cough and mucus production

Most people with COPD have a combination of both. The condition is most commonly caused by smoking, though long-term exposure to air pollution, dust, and chemicals can also contribute. A small percentage of cases are caused by Alpha-1 antitrypsin deficiency, a genetic condition.

Why Clinical Trials Matter for COPD

While current treatments — inhaled bronchodilators, corticosteroids, pulmonary rehabilitation, and oxygen therapy — help manage symptoms, they cannot reverse lung damage. Clinical trials are essential because they:

• Test new medications that may slow disease progression
• Evaluate biologics targeting specific inflammatory pathways
• Explore novel delivery methods for existing drugs
• Investigate regenerative approaches to repair lung tissue
• Improve quality of life through better symptom management

By participating in a clinical trial, you gain access to cutting-edge treatments and contribute to knowledge that helps future patients.

Current Areas of COPD Research

Triple Therapy Optimisation

The combination of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and long-acting beta-agonist (LABA) — known as triple therapy — is the gold standard for severe COPD. Current trials are investigating:

• Once-daily single-inhaler triple combinations for better adherence
• Optimal timing of triple therapy initiation
• Stepping down ICS in patients without eosinophilic inflammation

Biologic Therapies

Following the success of biologics in severe asthma, researchers are now exploring similar approaches for COPD with an eosinophilic phenotype. Trials are testing monoclonal antibodies that target:

• Interleukin-5 (IL-5) — reducing eosinophilic inflammation
• Interleukin-4 receptor alpha (IL-4Rα) — blocking multiple inflammatory signals
• Thymic stromal lymphopoietin (TSLP) — an upstream cytokine involved in airway inflammation

Alpha-1 Antitrypsin Replacement Therapy

For the small but significant group of COPD patients with Alpha-1 antitrypsin deficiency (AATD), trials are evaluating augmented replacement therapy, gene therapy approaches, and RNA-based treatments that could address the root genetic cause.

Exacerbation Prevention

COPD exacerbations — sudden worsening of symptoms — are a major cause of hospitalisation and disease progression. Trials are investigating new anti-inflammatory drugs, antibiotics for prevention, and digital monitoring tools that detect early warning signs.

Pulmonary Rehabilitation Innovation

Beyond traditional exercise-based rehabilitation, trials are testing virtual reality exercise programmes, telerehabilitation platforms, and personalised training protocols that can be delivered at home.

Types of Trials You May Find

Common trial designs for COPD include:

• Randomised controlled trials — you're randomly assigned to receive either the new treatment or the standard treatment (sometimes with a placebo)
• Open-label studies — both you and the researchers know which treatment you're receiving
• Crossover trials — you switch between treatments during the study, acting as your own comparison
• Observational studies — researchers monitor your condition over time without changing your treatment

Who Can Join a COPD Trial?

Eligibility varies by trial, but common criteria include:

• Confirmed COPD diagnosis — usually with spirometry showing FEV1/FVC ratio below 0.70
• Disease severity — some trials target moderate COPD (GOLD Stage 2), others focus on severe (Stage 3-4)
• Exacerbation history — many trials require at least 1-2 moderate or severe exacerbations in the past year
• Smoking status — some trials accept current smokers, others require you to have quit for a minimum period
• Eosinophil count — biologic trials often require a blood eosinophil count above a certain threshold
• Stable treatment — you're typically required to be on a stable COPD medication regimen for at least 4-12 weeks before enrolling

Major UK COPD Trial Centres

COPD research is conducted across the UK at major teaching hospitals and specialist respiratory centres, including:

• London — Royal Brompton Hospital, Guy's and St Thomas', University College Hospital
• Manchester — Manchester University NHS Foundation Trust, Wythenshawe Hospital
• Edinburgh — Royal Infirmary of Edinburgh, Queen's Medical Research Institute
• Glasgow — Glasgow Royal Infirmary, Queen Elizabeth University Hospital
• Leicester — Glenfield Hospital (specialist respiratory centre)
• Nottingham — Nottingham University Hospitals NHS Trust
• Newcastle — Royal Victoria Infirmary, Newcastle upon Tyne Hospitals
• Cambridge — Cambridge University Hospitals (Addenbrooke's)

How to Find and Apply for COPD Trials

Steps to get started:

• Talk to your respiratory consultant or GP — they may know of trials at your local hospital
• Search online — use TrialConnect's condition page for COPD to see actively recruiting UK studies
• Check the NIHR Clinical Research Network — the UK's research infrastructure supports COPD studies across the country
• Contact trial sites directly — each trial listing includes contact details for the research team

Frequently Asked Questions

Will I have to stop my current COPD medication?

Most trials allow you to continue your standard medications. Some may adjust your regimen as part of the study protocol, but this is always explained in detail during the informed consent process.

Are COPD clinical trials safe?

All clinical trials in the UK must be approved by an ethics committee and the Medicines and Healthcare products Regulatory Agency (MHRA). You'll be closely monitored throughout the study, and you can withdraw at any time.

Will I get paid for participating?

Most COPD treatment trials don't offer payment, but your travel expenses are typically reimbursed. Phase 1 healthy volunteer trials (which don't involve COPD patients) do offer compensation.

How long do COPD trials last?

Duration varies widely. Some trials last 12 weeks, while others follow participants for 1-2 years to assess long-term outcomes like exacerbation rates and lung function decline.

What if the treatment doesn't work for me?

If the investigational treatment isn't helping, the research team will discuss options with you. You always have the right to leave the trial and return to standard care.